MIM
CRSP icon

Monashee Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Monashee Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,000
Closed -$2.38M – 29
2026
Q1 		$2.38M Buy
+50,000
New +$2.64M 1.29% 27
2018
Q3 		– Hold
0
– – – 26
2017
Q1 		– Sell
-7,186
Closed -$141K – 70
2016
Q4 		$146K Buy
+7,186
New +$134K 0.07% 79

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Monashee Investment Management's CRSP Position: Q2 2026 in Review

Monashee Investment Management sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 50,000 shares — an estimated $2.38M sold.

Monashee Investment Management first reported a position in CRSP in Q4 2016 and held it in 2 quarters. The position peaked at $2.38M in Q1 2026. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Monashee Investment Management reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Monashee Investment Management sold 50,000 CRISPR Therapeutics shares in Q2 2026, an estimated $2.38M.
  • Monashee Investment Management first reported a position in CRISPR Therapeutics in Q4 2016 and held it in 2 quarters.
  • Monashee Investment Management's CRISPR Therapeutics position peaked at $2.38M in Q1 2026.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Monashee Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.